Procedure-specific bleeding risk assessment: a multidisciplinary expert consensus companion to the 2026 periprocedural anticoagulant management guidelines
Related Experiment Videos
Anne Godier1, Stéphanie Roullet2, Julien Lanoiselée3
1Université Paris Cité, service d'anesthésie-réanimation, AP-HP, Hôpital Georges Pompidou, UMRS_1140, F-75006 Paris, France.
Background:
Periprocedural anticoagulant management requires balancing thrombotic risk against procedure-specific bleeding risk. Existing procedure bleeding risk classifications are fragmented across specialties, inconsistent in methodology, and rarely extend beyond a few procedural domains, limiting their clinical applicability.
Objective:
To develop a comprehensive, standardized, procedure-specific bleeding risk classification to accompany the 2026 GIHP-SFAR periprocedural anticoagulant management guidelines.
Methods:
A formal multidisciplinary consensus was conducted under the auspices of GIHP and SFAR, in collaboration with 24 surgical and interventional specialty societies. For each procedural domain, a working group performed a systematic literature review. Procedures were classified into four tiers: no bleeding risk, low bleeding risk, high bleeding risk, and very high bleeding risk. A specific category was created for procedures carrying particular contextual risk (e.g., anatomical site, patient factors, or need for reversible anticoagulation). Consensus was reached by the full expert panel.
Results:
Twenty-four procedural domains were classified, ranging from regional anaesthesia and digestive endoscopy to cardiac surgery, neurosurgery, and ophthalmology. Each domain provides a procedure-specific bleeding risk table, with narrative supporting evidence. Procedures warranting delayed resumption of anticoagulation (≥72 hours) or use of short-acting/reversible anticoagulants are identified. The classification covers common and complex surgical scenarios, including those with limited published evidence where structured expert opinion was applied.
Conclusion:
This companion document provides clinicians with a standardized, evidence-based, procedure-specific bleeding risk framework across 24 domains to support individualized periprocedural anticoagulant decisions in daily practice.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pre-Procedural Guidelines for Assessing Blood Pressure
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...